A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
Who is this study for? Patients with Irritable Bowel Syndrome
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• • Age ≥ 18 years,
‣ Man and Women, Negative pregnancy test and effective contraception,
⁃ IBS defined by the Rome criteria IV
⁃ During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.
⁃ IBS Treatment stable for 1 month
Locations
Other Locations
Egypt
Sherief Abd-Elsalam
RECRUITING
Tanta
Contact Information
Primary
Sherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com
00201147773440
Time Frame
Start Date: 2019-11-01
Estimated Completion Date: 2030-12-30
Participants
Target number of participants: 60
Treatments
Active_comparator: Mebeverine
Mebeverine 3 times daily for 3 months
Experimental: Ethosuximide
Ethosuxemide 3 times daily for 3 months
Experimental: Pentoxyifylline
pentoxyifylline 2 times daily for 3 months
Related Therapeutic Areas
Sponsors
Leads: Tanta University